Search Results - liver+disorders

5 Results

Sort By:

Recombinant CTRP3 as Protein Therapeutics for Non-alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD), a major cause of liver dysfunction, is characterized by intrahepatic triacylglycerol (TAG) overaccumulation resulting from excess dietary lipids and de novo fatty acid synthesis. NAFLD is closely linked to insulin resistance and uncontrolled gluconeogenesis and, hence, is often associated with obesity. Yet,...

Published: 6/20/2024 | Inventor(s): Jonathan Peterson, Guang Wong

Keywords(s): Biologics, Disease Indication, Liver Disorders, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Hepatology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities

Treatment of Acute Liver Injury and Hepatic Failure by Mobilization of Bone Marrow Derived Stem Cells

Acute Liver Failure (ALF), typically due to drug poisoning or viral hepatitis, accounts for around 10,000 deaths per year in the United States. Treatment options are severely limited: supportive observation in the hopes of spontaneous recovery or liver transplant. Liver transplant is an imperfect solution for these patients with extraordinary resource...

Published: 6/20/2024 | Inventor(s): Andrew Cameron

Keywords(s): Acute Liver Failure, Biologics, Cell Therapy, Disease Indication, Liver Disorders, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Whole cell

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Hepatology > Acute Liver Failure, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Cell Therapies, Clinical and Disease Specializations > Hepatology, Technology Classifications > Therapeutic Modalities

Quantitative Enhancement Measurement of Hypervascular Liver Lesions on MRI

INVENTION NOVELTY The proposition of this invention is to provide quantitative assessment of enhancement to the entire tumor volume in Hepatocellular carcinoma cases. This process will remove the subjectivity of treatment response assessment and allow for a more direct comparison of pre- and post-TACE treatment response. Various methods to measure...

Published: 6/20/2024 | Inventor(s): Jean-Francois Geschwind, Mingde Lin, Nikhil Bhagat

Keywords(s): Disease Indication, Image Display Software, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Liver Disorders, Magnetic Resonance Imaging (MRI)

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Hepatology, Technology Classifications > Computers, Electronics & Software, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices

Synthesis of High Affinity Liver-Targeting Reagent based on Multivalency Effect of Sugar Binding

Value Proposition· Non-invasive imaging agent correlates with liver function and can detect low levels of liver-fibrosis.· Imaging agent has higher sensitivity than traditional liver function tests.· Glyco-ligand can potentially be used to target other drugs to the liver. Technology DescriptionCurrent methods for detecting liver...

Published: 6/20/2024 | Inventor(s): Mei-Hui Wang, Reiko Lee, Wuu-Jyh Lin, Yuan Lee

Keywords(s): Disease Indication, Liver Disorders, Novel, Predicted Novelty, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Hepatology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Hepatology > Acute Liver Failure, Technology Classifications > Diagnostics > In Vivo Diagnostics, Clinical and Disease Specializations > Hepatology > Liver Fibrosis, Technology Classifications > Diagnostics > Diagnostic Imaging

Recognition of Critical CYP2E1 Epitopes

TITLE: New Diagnostic Test for Drug Induced Liver Injury and Chronic Hepatitis CCASE NUMBER: C10654UNMET NEED Idiosyncratic drug-induced acute liver failure (Id-ALF) is the third most common cause of acute liver failure in the United States and is the leading cause for drug removal from the market. A type of Id-ALF develops in susceptible...

Published: 6/20/2024 | Inventor(s): Dolores Njoku

Keywords(s): Acute Liver Failure, Antigens, Assay, Biologics, Clinical Diagnostics, Disease Indication, Immunotherapy, In Vitro Diagnostics, Liver Disorders, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Hepatology > Acute Liver Failure, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Hepatology, Technology Classifications > Research Tools